The peculiar higher solubility of drug nanocrystals compared to macrocrystals appeals to the pharmaceutical field. Indeed, until now, about 70 % of the potential drug candidates are discarded due to low bioavailability related with poor solubility in water. Since a modern and efficient design strategy for nanocrystal-based delivery systems requires the knowledge of the theoretical relation between nanocrystal size and solubility, the aim of this paper is to build up a physically-oriented thermodynamic model relating to nanocrystal dimensions with their melting temperature, enthalpy, solubility and dissolution rate. In particular, the developed model will be applied to vinpocetine, a poorly soluble drug used in the treatment of various types of cerebrovascular circulatory disorders.
Introduction
Regardless of the administration route, the key factor for the success and reliability of any formulation is drug bioavailability, defined as the rate and extent at which the active drug is absorbed from a pharmaceutical form and becomes available at the site of drug action. 1 Although metabolism and physiological factors highly affect drug absorption by living tissues, bioavailability is strongly dependent on drug permeability through cell membranes and on drug dissolution in physiological fluids. In particular, dissolution becomes the most important factor in terms of bioavailability for poorly water-soluble -highly permeable drugs (class II drugs according to the Amidon classification 2 ). This aspect is of paramount importance if we know that, at present, about 40 % of the drugs being in the development pipelines are poorly soluble, up to 60 % of synthetized compounds are poorly soluble, 3 and 70 % of the potential drug candidates are discarded due to low bioavailability related with poor solubility in water. 4 Examples of commonly marketed drugs that are poorly soluble in water (less than 100 mg cm -3 ) include analgesics, cardiovasculars, hormones, antivirals, immune suppressants and antibiotics. 5 Since it is well known that solubility increases with drug nanocrystal size decrease, 5 this paper focuses on the theoretical relation existing between nanocrystal size, solubility and dissolution rate. To this end, a thermodynamic model relating to nanocrystal dimensions (radius), melting temperature/ enthalpy and solubility will be presented and discussed.
Materials and methods
Vinpocetine (C 22 H 26 N 2 O 2 , molecular weight M w = 350.45 (-)), a kind gift from Linnea SA ( Riazzino-Locarno, CH, Switzerland), is a semisynthetic derivative of the Vinca minor L. alkaloid vincamine 6 used for the treatment of cognitive disorders and related symptoms such as cerebral infarction, cerebral hemorrhage residual and cerebral arteries cirrhosis. 7 This base-type drug (pKa = 7.1) 8 was chosen as a model drug because it is practically insoluble in water (1.6 mg mL -1 in pH = 7.4 at 37 °C). 9 Vinpocetine melting temperature (T m∞ = 149.6 °C), melting enthalpy (DH m∞ = 94600 J kg -1 ) and DC p (difference in specific heat capacity at constant pressure between the liquid ( ) was evaluated according to the group contribution approach 10, 11 implemented by the Breitkreutz software. 12 Determination of the solid vinpocetine -vapor surface tension ( 
where q i is the contact angle of liquid "i" on solid vinpocetine, b is a model fitting parameter and ). Contact angles (water, q 1 = 82°; ethylene glycol, q 2 = 61°; dimethyl sulfoxide, q 3 = 37°; diiodomethane, q 4 = 33°) were measured by the tensiometer G10, Kruss, GmbH, Hamburg, D. Determination of the liquid vinpocetine -vapor surface tension ( lv  g ) was performed according to the Parachor method:
The solid-liquid vinpocetine ( sl  g ) surface tension was evaluated according to the Young equation for pure substances (q = 0):
The solid vinpocetine -water ( sl 1 g ) surface tension was evaluated according to the Young equation 15 (q 1 = 82°):
The Tolman length d 16 for vinpocetine (d is equal to 1/3 of vinpocetine molecule diameter 17 ) was evaluated resorting to the knowledge of liquid vinpocetine molar volume M v and assuming a spherical shape for the vinpocetine molecule:
where N A is the Avogadro number. Finally, the Crystallographic Information File (CIF) of vinpocetine was extracted from the International Union of Crystallography database. 18 Vinpocetine shows a monoclinic crystal system with the following unit cell parameters: a = 0.8907 nm, a a = 90°, b = 0.953 nm, b b = 106.57°, c = 0.11286 nm, g c = 90°, unit cell volume 0.9182 nm 3 . Vinpocetine unit cell corresponds to a sphere of radius approximately equal to 0.5 nm.
Drug dissolution
The dissolution of a solid in a solvent is a rather complex process determined by a multiplicity of physicochemical properties of the solute and solvent. 5 Typically, for a fixed solid-solvent couple, solid solubility, liquid environment fluido-dynamic conditions, dissolution surface and solid wettability are the key factors affecting the dissolution kinetics. 5, 19 In addition, for what concerns solid solubility, temperature and pH play predominant roles whilst pressure is generally less important. However, pH becomes the key parameter for the crowded class of small organic drugs behaving as weak acids or bases. 20 Indeed, as the solubility of the dissociated form can be much higher than that of the un-dissociated form, the relation between environmental pH and drug pKa being fundamental. For example, nimesulide (pKa = 6.5), 21 a weak acid nonsteroidal anti-inflammatory drug, increases its solubility by about one order of magnitude, from pH = 1.2 (37 °C: solubility ~ 10 mg mL -1 ; nimesulide is un-dissociated) to pH = 7.5 (37 °C: ~ 100 mg mL -1 ; nimesulide is dissociated). 22 When temperature and pH are fixed, it is well known that solubility also depends on the solid melting temperature and enthalpy 23 that, in turn, depend on solid crystals dimensions, as discussed in the next sections 4 and 5. In particular, the smaller the crystals, the lower their melting temperature/enthalpy and, consequently, the higher their solubility. Accordingly, in order to discern the effect of equilibrium (solid solubility) and kinetics (fluido-dynamic conditions, wettability, and dissolution surface) factors, let us focus on the dissolution process of a solid phase subdivided in many spherical particles, having the same diameter. In addition, we assume that particles do not aggregate during dissolution and that the initial amount of the solid phase (M 0 ) is so high that at equilibrium (i.e. when solid concentration reaches solubility in the liquid phase) the variation of the solid particles radius is negligible. Accordingly, for the generic solid particle, the physical situation we are referring to is depicted in Fig. 1 . Dissolution can be considered as a consecutive process driven by four energy changes DE i : 1) Contact of the solvent with the solid surface (wetting), which implies the production of a solid-liquid interface starting from solid-vapor one (DE 1 = DE w ) 2) Breakdown of molecular bonds of the solid (fusion; (DE 2 = DE f )) 3) Solid molecules transfer to the solid-liquid interface (solvation; (DE 3 = DE s )) 4) Movement of the solvated molecules from the interfacial region into the bulk solution (diffusion; (DE 4 = DE d )). The sum of the energies relative to the four mentioned steps represents the total energy required for solid dissolution. Obviously, the higher the dissolution energy required, the lower the dissolution kinetics. In order to connect these four energy contributes to the equilibrium and the kinetics parameters ruling solid dissolution, we need a mathematical model linking the time evolution of the solid concentration profile (C(r)) in the stagnant layer with the solid molecules concentration in the bulk liquid (C b ). Obviously, C(r) is given by the solution of the so-called second Fick's law:
where t is time, r is the radial position and D is the solid molecules diffusion coefficient in the stagnant layer (D can be considered constant in the stagnant layer thickness 5 ). Assuming that a pseudo-stationary condition can be rapidly achieved in the stagnant layer (this hypothesis is supported by the numerical solution of eq. ) 5 and stagnant layer thickness (h SL ) lower than 20 mm), eq. (6) becomes:
The solution of eq. (7), subjected to the following initial boundary conditions: initial:
boundary:
leads to the solid molecule concentration profile C(r) in the stagnant layer surrounding the solid particles (see details in Appendix):
where R c is the particle radius (supposed time independent; see Fig. 1 ), R s is the stagnant layer radius (supposed time independent; see Fig. 1 ), 1/k m is the solid-liquid interface mass transfer resistance while
is the so-called dissolution constant. 5 While eq. (8) simply states that the stagnant layer is initially drug empty, eq. (9) affirms that, in R s , the solid molecules concentration equals the bulk one. Finally, eq. (10) affirms that solid molecules flux at the solid-liquid interface (R c ) depends on both k m and the difference between drug solubility (C s ) and actual local drug concentration (C(R c )). An inspection of eq. (11) reveals that C(R c ) develops from a fraction of C s (for t = 0, C b = 0 and
to C s for a very long time. This is due to the mass transfer resistance (1/k m ) that accounts also for solid surface wettability problems. Indeed, when this resistance is zero, C(R c ) is always equal to C s .
In order to complete the dissolution model, it is necessary to consider the following equation:
F i g . 1 -Solid drug dissolution in a solvent liquid phase implies overcoming four energy barriers represented by solid wetting (DE w ), breakdown (fusion) of solid molecular bonds (DE f ), drug molecules solvation (DE s ) and drug molecules diffusion through the solvent stagnant layer to reach the bulk solvent (DE d ). These energies affect, in different manners, the mass transfer coefficient (k m ) at the solid/liquid interface, the dissolution constant k d and the drug solubility C s (DE f ). It is important to stress that, due to possible solid surface wetting problems, the solid molecule concentration at the solid/liquid interface (C(R c )) can be lower than C s , as shown by eq. (11).
Eq. (12) imposes that the increase rate of the solid molecules concentration in the bulk liquid (volume V) depends on the mass flux in R s and on the release surface ( 
Assuming, for the sake of simplicity, that the ratio R c /R s does not sensibly depend on R c , eq. (13) indicates that a reduction of particles radius (R c ), being constant V and M 0 , implies the improvement of the dissolution kinetics as the dissolution surface increases proportionally to M 0 /(R c r s ). However, it will be demonstrated in the following sections 4 and 5 that R c reduction also implies a dissolution kinetics increase due to C s increase. It is worth noting that this last effect becomes important only for very small particles (R c < 50 nm). On the basis of eq. (13) 
Nanocrystal solubility dependence on melting enthalpy/temperature
The peculiar behavior of very small crystals is explained by the different characteristics of the surface and bulk phases. Indeed, due to their less confined arrangement (fewer inter-atomic bonds), 24 surface atoms/molecules are characterized by a higher energy content with respect to bulk atoms/molecules. Consequently, lattice breakdown on crystal surface would require less energy and would be favored over bulk lattice breakdown. This theoretical interpretation, supported by experimental data and molecular dynamics simulations, 25 clearly reveals the importance of surfaces as stand-alone phases. Obviously, the effect of surfaces becomes relevant (i.e., appreciable at the macroscopic level) only when the number of surface atoms/molecules is not negligible compared to that of the bulk atoms/molecules, which happens when the crystal surface/volume ratio is very high, i.e. when crystal size falls in the nanometer range. 26 The immediate consequence of the different behavior of surface atoms/molecules is that nanocrystals are characterized by a decreasing melting temperature/enthalpy as the nanocrystal radius (R c ) decreases. The thermodynamic equilibrium condition between a liquid phase (solvent) and a solid phase (drug) yields to the C s dependence on solid crystals radius R c , provided that the solid surface properties are properly accounted for. 26, 27 Assuming that only the drug partitions between the two phases (this means that the solvent does not go inside the drug), the equilibrium condition requires that the solid drug fugacity ( 
where g d and X d are, respectively, the drug activity coefficient and solubility (molar fraction) in the solvent,
f is the drug fugacity in the reference state, while s d f is the drug fugacity in the solid state. Thus, X d is given by:
If we assume that l d
f is the fugacity of the pure drug in the state of undercooled liquid at system temperature (T) and pressure (P), the ratio
f f can be evaluated as the variation of the molar Gibbs free energy (Dg da ) between the state of undercooled liquid drug (state d) and solid (nanocrystalline) drug (state a) (see Fig. 2 
where R is the universal gas constant, while the enthalpy (Dh ba , Dh cb , Dh dc ) and entropy (Ds ba , Ds cb , Ds dc ) variations can be evaluated as:
cb m
where T m is the nanocrystal melting temperature, 
where
Finally, molar solubility X d can be expressed as the mass/volume solubility C s :
where M d and M s are drug and solvent molecular weight, respectively, while r sol is solvent density. In order to understand the effect of nanocrystal radius R c decrease on X d or C s , the dependence of Dh m and T m on R c has to be necessarily expressed.
Melting enthalpy/temperature dependence on nanocrystal radius
The physics of nanocrystals melting can be described by the three different mechanisms 28 reported in Fig. 3 . According to the Homogeneous Melting approach (HM), the solid (spherical) crystal is in equilibrium with a liquid (spherical) phase having the same mass and both are embedded in the vapor phase. The Liquid Skin Melting theory (LSM) assumes the formation of a thin liquid layer over the solid core. The thickness of the liquid layer remains constant until the solid core completely melts. On the contrary, in the Liquid Nucleation and Growth approach (LNG), the liquid layer thickness increases as it approaches the melting temperature. Accordingly, the solid core melting takes place when the liquid layer thickness is no longer negligible in comparison to the solid core radius.
In a previously published work, 26 we theoretically demonstrated the connection existing among melting temperature/enthalpy and nanocrystals radius (R c ). In particular, efforts were made to properly express the infinitesimal, reversible, variation of the internal energy E (dE) referred to the closed system composed of solid drug, liquid drug and vapor drug. In that demonstration, the connection among dE and the LSM, LNG, HM frames (i.e. the relations existing among the solid, liquid and vapor phases; see Fig. 3 ) was introduced only in a late stage of the demonstration. In this work, on the contrary, we would like to follow a more physically-oriented strategy aimed to immediately consider the relations existing among the three phases according to the LSM, LNG, HM mechanisms. We believe that the coincidence of the final results, coming from the two approaches, strengthens the whole theoretical approach.
LSM and LNG mechanisms
The starting point is the definition of dE for the closed system (no matter or energy exchanges with the surroundings, i.e. system volume, entropy and moles number are constant) composed of one component and 3 phases (s solid, l liquid, v vapor) 15 whose spatial organization is that of the LNG and LSM melting mechanisms (see Fig. 3 ):
, E lv represent the solid, liquid, vapor, solid/liquid and liquid/vapor phase internal energy, respectively. Assuming that a) the contribution of the first and the second curvatures to system internal energy, E, is negligible (this is strictly true for planes and spheres), and that b) thermal and chemical equilibrium is attained among the bulk and surface phases (same temperature and chemical potential in all bulk and surface phases), eq. (22) becomes:
where P is pressure, V is volume, A is interfacial area, g is interfacial tension while superscripts sl and lv are solid-liquid and liquid-vapor, respectively. In the light of the closed system hypothesis (dV l = -dV v -dV s ), we have:
The system equilibrium condition (dE = 0) implies:
These relations can be inserted in the GibbsDuhem equation referring to the solid, liquid and vapor phases: 
Inserting in eqs. (30) 
Equating eqs. (32) to (33), we have:
(34) becomes:
where Ds m is the molar melting entropy (s l -s s ). In order to make eq. (35) operative, it is necessary to evaluate the two differential terms involving areas, volumes and surface tensions. In particular, for spherical crystals, we have:
where R sl and R lv represent the curvature radius proper to the solid-liquid and liquid-vapor interface, respectively (see Fig. 3 ). In addition, the surface tension g dependence on the interface curvature radius, as suggested by Tolman, 16 is as follows:
where g ∞ and g are, respectively, the surface tension competing to a flat surface (infinite curvature radius) and a surface of curvature radius R 
where Dh m is the molar melting enthalpy. The integration of eq. (40) between the melting temperature of the infinitely large crystal (T m∞ , R lv →∞, R sl → ∞) and the melting temperature (T m ) of the crystal of radius R sl , leads to:
or, expressing the enthalpy per unit mass instead of per mole:
where r l and r s are, respectively the density of the liquid and solid phases. Establishing a relation between R lv and R sl is now essential. To this end, a generalized version of the strategy adopted by Coceani 27 can be undertaken. This approach relies upon the fact that, very often, drug crystals' melting occurs in the presence of a drug amorphous solid that becomes liquid before the melting temperature. Indeed, as the glass transition temperature of the amorphous drug is lower than the crystals' melting temperature (whatever R sl ), the amorphous drug will be liquid before the nanocrystals melting. Thus, at melting point, the nanocrystals mass fraction, X nc , can be evaluated as: 
Consequently, we have:
It is easy to verify that the LSM condition occurs for X nc ≈ 1 (the amorphous, liquid phase is virtually absent; R lv ≈ R c ), while LNG condition takes place for X nc ≈ 0 (nanocrystal melting occurs in a virtually infinite liquid phase, R lv ≈ ∞). For 0 < X nc < 1, we can account for what usually happens during the melting of organic drug crystals embedded in a polymeric stabilizing carrier. 27 When X nc is unknown, its determination implies an iterative procedure based on the knowledge of the differential scanning calorimetry trace referring to the melting of the amorphous/crystal drug. 26, 27 It is interesting to note that the results of the approach presented in this paper lead to what was previously demonstrated following a different path. 26 
HM mechanism
In the case of the homogeneous melting, the expression of the infinitesimal, reversible, variation of the internal energy E reads:
It is worth noting that eq. (45) . Indeed, in the HM case, the solid/liquid interface no longer exists (see Fig. 3 ), while it is replaced by the solid/vapor interface. Starting from eq. (45) and following a procedure analogue to that shown for the LSM and LNG approaches, we obtain:
Remembering that in the HM case the solid and liquid phases are characterized by the same mass, the relation between R lv and R sl (= R c ) is:
Results
In order to integrate eq. (42) and (46), it is necessary to know the DH m dependence on R c and T m . Therefore, the thermodynamic relation used by Zhang and co-workers, 29 holding regardless of nanocrystal nature (organic or inorganic) and characterized by easily determinable parameters, seems appropriate:
where DH m∞ is the specific melting enthalpy (J Kg -1 ) referred to the infinite radius drug crystal, DC p (J kg -1 K -1 ) is the difference between the liquid and solid drug specific heat capacity at constant pressure. As DC p is almost temperature invariant, the integral in eq. (48) can be approximated by DC p (T m∞ -T m ). Figs. 4A and 4B indicate, respectively, the reduction of vinpocetine melting temperature (T m ) and melting enthalpy (DH m ) with crystal radius (R c ) according to eq. (42) in the case of liquid skin melting (X nc = 1), liquid nucleation and growth (X nc ≈ 0) mechanisms. It can be seen that, for both mechanisms, an appreciable effect of R c reduction takes place for R c < 50 nm, while T m and DH m undergo a considerable reduction for R c < 10 nm. On the contrary, the effect of X nc seems limited, and this is mainly due to the fact that vinpocetine density does not significantly change from the solid to the liquid state (see eq. (42)). Interestingly, we found similar results using other poorly water soluble small organic drugs, i.e., nifedipine, griseofulvin 26 and nimesulide. 27 In the case of griseofulvin and nifedipine, model predictions were substantially confirmed by means of the X rays evaluation of nanocrystal dimensions. 26 Fig . 5A shows, according to eq. (20), the increase of vinpocetine nanocrystal solubility (C s ) with R c reduction for two different X nc values (1, LNG; ≈ 0, LNG). Also in this case, an appreciable effect takes place for R c < 50 nm and the effect exerted by X nc is not so relevant. For the smallest nanocrystals, C s is about 3 times that of the infinitely large vinpocetine crystals (C s∞ ).
While model verification can be conducted, in its thermal part, e.g. with X ray analysis, 26 the proof of the solubility enhancement is much more difficult due to the experimental difficulty of measuring the solubility of drug nanocrystals and amorphous drugs. [30] [31] [32] [33] Some useful considerations can be drawn by making a comparison between our model and the well-known Ostwald-Freundlich model: Fig. 4A Fig.  5B (dashed line) jointly with the predictions of our approach (solid thin and thick lines). It can be noticed that for small crystals eq. (49) leads to an unreasonable solubility increase keeping in mind that, in general, the solubility increase of amorphous drugs (not too dissimilar from vinpocetine) have been theoretically estimated in the range (7 -100). 35 On the contrary, the prediction of our model seems more reasonable. Nevertheless, we recognize that the difficulty connected to the experimental measurement of nanocrystals solubility leaves this question still open.
Conclusions
In this paper, we demonstrated the theoretical correctness of our previous approach aimed at the evaluation of melting temperature/enthalpy depression with decreasing nanocrystals radius. Indeed, by means of a more physically oriented approach, we confirmed the theoretical results of our previous work. In addition, considering these results in the frame of drug dissolution, we proved that nanocrystals can play a very important role in the pharmaceutical field as they can enhance the bioavailability of poorly soluble -highly permeable drugs. Indeed, the concomitant decrease in melting temperature and enthalpy has a double beneficial effect on drug dissolution and, ultimately, on drug bioavailability. On the one hand, melting enthalpy reduction (DH m = DE f at constant temperature and pressure, see Fig. 1 ) improves the dissolution process by reducing one of the most important energy-related steps involved in drug dissolution (i.e. breakdown of the crystalline network (step 2 in Fig. 1 ), connected to the mass transfer resistance 1/k m ). On the other hand, it increases drug solubility (see eq. (20) and Fig. 5A ). As a result, the dissolution rate can be increased considerably.
Interestingly, despite the mathematical (not physical) complexity connected to the theoretical study of the relation existing between nanocrystals size and solubility, the preparation of drug nanocrystals is no longer problematic since many reliable technologies are available nowadays. 36, 37 This is of particular interest if we know that, until now, about 70 % of the potential drug candidates are discarded due to low bioavailability related with poor solubility in water. 4 Obviously, the problem of bioavailability enhancement of poorly soluble drugs also requires the estimation of drug solubility in the drug amorphous state that can be considered as a nanocrystal of vanishing dimensions. In this respect, the work of Bogner and co-workers 35 is a very interesting theoretical contribution.
APPENDIX
The solution of eq. (7) 
implies a double integration in space:
first:
second:
The integration constants A 1 and A 2 can be evaluated by means of the boundary conditions expressed by eqs. (9) and (10):
From eqs. (9) and (10), we have:
The solution of the linear system represented by eqs. (A3) and (A4) leads to the determination of the integration constants A 1 and A 2 :
Inserting these expressions for A 1 and A 2 into eq. (A2), leads to eq. (11) .
Starting from eq. (11), it is possible to solve eq. (12) since we now have an analytical expression for the spatial concentration derivative:
Substitution of eq. (A6) into eq. (12) leads to:
Remembering that the number of particles is given by N p = M 0 /((4/3)prR c 3 ) and that k d = D/h SL , eq. (A7) can be rearranged to give:
This first order differential equation can be solved by means of standard techniques to give eq. (13). Dg da -molar Gibbs energy variation from state "d" (under-cooled liquid drug at T and P) and state "a" (drug nanocrystals at T and P), J mol -1
Dg m -melting molar Gibb energy, J mol -1
Dh da -molar enthalpy variation between state "d" (under-cooled liquid drug at T and P) and state "a" (drug nanocrystals at T and P), J mol -1
Dh ba -molar enthalpy variation between state "b" (drug nanocrystals at T m and P) and state "a" (drug nanocrystals at T and P), J mol -1
Dh cb -molar enthalpy variation between state "c" (liquid drug at T m and P) and state "b" (drug nanocrystals at T m and P), J mol -1
Dh dc -molar enthalpy variation from state "d" (under-cooled liquid drug at T and P) to state "c" (liquid drug at T m and P), J mol Ds da -molar entropy variation between state "d" (under-cooled liquid drug at T and P) and state "a" (drug nanocrystals at T and P), J mol -1
Ds ba -molar entropy variation between state "b" (drug nanocrystals at T m and P) and state "a" (drug nanocrystals at T and P), J mol -1
Ds cb -molar entropy variation between state "c" (liquid drug at T m and P) and state "b" (drug nanocrystals at T m and P), J mol -1
Ds dc -molar entropy variation from state "d" (under-cooled liquid drug at T and P) to state "c" (liquid drug at T m and P), J mol q i -contact angle of liquid "i" on solid drug, degrees
